Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL): first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG) - Pflug, Natali; Zenz, Thorsten (Blood, 2014)
Gesehen am 09.07.2015